Oncos Therapeutics develops new cancer therapies based on its next generation oncolytic viruses. The company's unique Advanced Therapy Access Program was started in 2007 for cancer patients in whom standard-of-care therapies have failed. Today, 200 patients have undergone individually tailored oncolytic virus therapy suggesting strong safety and efficacy. The program is based on extensive scientific research at the University of Helsinki and serves as the foundation for ongoing clinical development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.